Angiotensin-converting enzyme expression in human carotid artery atherosclerosis

Hypertension

Volumn 35, Issue 1 II, 2000, Pages 353-359

  Fukuhara, Masayo ^a   Geary, Randolph L ^a   Diz, Debra I ^a   Gallagher, Patricia E ^a   Wilson, John A ^a   Glazier, Steven S ^a   Dean, Richard H ^a   Ferrario, Carlos M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin converting; Carotid arteries; Enzyme; Hybridization; Immunohistochemistry; Macrophages

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

AGED; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CLINICAL ARTICLE; CONFERENCE PAPER; ENZYME LOCALIZATION; ENZYME SYNTHESIS; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033977163     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.35.1.353     Document Type: Conference Paper

References (23)

1. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996;94:2756-2767.
2. Dzau VJ. Vascular renin-angiotensin system and vascular protection. J Cardiovasc Pharmacol. 1993;22(suppl 5):S1-S9.
3. Strawn WB, Ferrario CM. Tallant EA. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension. 1999;33(pt II): 207-211.
4. 1-receptor blockade inhibits monocyte activation and adherence in transgenic (mRen2)27 rats. J Cardiovasc Pharmacol. 1999; 33:341-351.
5. Ferrario CM, Deitch JS, Dean RH, Strawn WB. Hypertension and atherosclerosis: a mechanistic understanding of disease progression. Cardiovasc Risk Factors. 1996;6:299-310.
6. Hope S, Brecher P, Chobanian AV. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens. 1999;12(pt 1):28-34.
7. Chobanian AV, Haudenschild CC, Nickerson C, Hope S. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1992;20:473-477.
8. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15(suppl 5):S65-S72.
9. Ferrario CM, Chappell MC, Kivlighn S, Strawn WB. Fatty streak formation is inhibited by losartan in monkeys with diet-induced hypercholesterolemia. Hypertension. 1999;34:329. Abstract.
10. Keidar S, Attias J, Smith J, Breslow J, Hayek T. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 1997;236:622-625.
11. Strawn WB, Chappell MC, Ferrario CM. Losartan reduces LDL susceptibility to oxidation and circulating markers of inflammation in hyperlipoproteinemic monkeys. Hypertension. 1999;34:328. Abstract.
12. Potter DD, Sobey CG, Thompkins PK, Rossen JD, Heistad DD. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation. 1998;98:800-807.
13. Mondy JS, Lindner V, Miyashiro JK, Berk BC, Dean RH, Geary RL. Platelet-derived growth factor ligand and receptor expression in response to altered blood flow in vivo. Circ Res. 1997;81:320-327.
14. Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Tregear G, Corvol P. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Nad Acad Sci USA. 1988; 85:9386-9390.
15. Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull W Jr, Richardson M, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of the intima of human arteries and of its atherosclerosis-prone regions: a report from the committee on vascular lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1992;85:391-405.
16. Ohishi M, Ueda M, Rakugi H, Naruko T, Kojima A, Okamura A, Higaki J, Ogihara T. Relative localization of angiotensin-converting enzyme, chymase and angiotensin II in human coronary atherosclerotic lesions. J Hypertens. 1999;17:547-553.
17. Ohishi M, Ueda M, Rakugi H, Naruko T, Kojima A, Okamura A, Higaki J, Ogihara T. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens. 1997;15:1295-1302.
18. Jeziorska M, McCollum C, Wooley DE. Observations on bone formation and remodeling in advanced atherosclerotic lesions of human carotid arteries. Virchows Arch. 1998;433:559-565.
19. Fuster V, Badimon JJ, Chesebro JH. Atherothrombosis: mechanisms and clinical therapeutic approaches. Vasc Med. 1998;3:231-239.
20. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
21. Libby P. The interface of atherosclerosis and thrombosis: basic mechanisms. Vasc Med. 1998;3:225-229.
22. Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE, Sukhova GK, Libby P. Lipid lowering by diet reduces matrix metallo-proteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation. 1998;97: 2433-2444.
23. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res. 1999;84: 695-703.